A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Acronyms KINECT; KINECT-1
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 04 Dec 2017 According to a Neurocrine Biosciences media release, Results (n=373) of pooled population from KINETIC-1,KINETIC-2,KINETIC-3 studies presented at the College of Neuropsychopharmacology (ACNP) Annual Meeting.
    • 08 Jun 2017 Results (n=373) of pooled population from KINETIC-1,KINETIC-2,KINETIC-3 studies presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 08 Jun 2017 Results (n=430) of pooled long-term exposure analysis using patient data from NCT01688037, NCT02274558, NCT02405091 trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top